FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study

Diabetes Mellitus Clinical Trial

Official title:

FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03820050
• Other study ID #: ADC-US-VAL-18175
• Status: Completed
• Start date: January 29, 2019
• Est. completion date: June 14, 2019

Study information

• Verified date: June 2019
• Source: Abbott Diabetes Care
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to characterize the Freestyle Libre Flash Glucose Monitoring System in pediatric subjects with respect to YSI reference venous plasma sample measurements.

Description:

Up to 250 subjects will be enrolled at up to six (6) clinical research sites in the United States. Subjects will wear two Sensors. Each Sensor will have a paired Reader that will be given to the subject. All Readers will be masked during the study (i.e. subjects will not be able to view glucose results obtained from the Sensor on the Reader screen). Subjects will be asked to perform at least 4 capillary Blood Glucose (BG) tests per day using the primary Reader. Interstitial glucose readings from each Sensor will be obtained with the corresponding Readers immediately following each BG test. Subjects will be instructed to report any problems with the device. Subjects will make three (3), four (4) or five (5) scheduled visits to the clinical study site, including the Enrollment/Screening Visit (Visit 1). Based on the subjects weight, subjects will have up to two (2) in-clinic visits during which intravenous blood draws and YSI reference testing will occur.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 144
• Est. completion date: June 14, 2019
• Est. primary completion date: June 14, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 17 Years

Eligibility

Inclusion Criteria:

• Subject must be between the ages of 4 and 17 years of age at the time of study enrollment.

• Subject must have type 1 or type 2 diabetes.

• Subjects age 11 and older must require insulin therapy through an insulin pump and/or multiple daily insulin injections (at least 3 injections daily).

• Willing to perform a minimum of 4 finger sticks per day while wearing the sensor in the study.

• Subject and/or guardian must be able to read and understand English.

• For subjects age 6 and older: willing to allow medical personnel to insert an IV catheter in the arm to allow for venous blood flow samples to be obtained per the study protocol.

• For subjects age 11 and older: subject is willing to have their blood sugar manipulated during one or more in-clinic sessions.

• In the investigator's opinion, the subject must be able to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol.

• At the time of enrollment, subject must be available to participate in all study visits.

• Known insulin sensitivity factor (only applicable to subjects age 11 and older).

• Subject's parent, guardian or legally authorized representative must be willing and able to provide written informed consent.

• Subject must be willing and able to provide written signed and dated informed assent when appropriate.

Exclusion Criteria:

• Subject is 18 years of age or older.

• Subject has a history of hypoglycemia unawareness (only applicable to subjects age 11 and older).

• Subject has known allergy to medical grade adhesive or isopropyl alcohol used to disinfect skin.

• Subject is known to be pregnant or becomes pregnant during the study (applicable to female subjects only).

• Subject has extensive skin changes/diseases at the proposed application sites that could interfere with device placement or the accuracy of interstitial glucose measurements. Such conditions include, but are not limited to extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, dermatitis herpetiformis, skin lesions, redness, infection or edema.

• Subject has had an episode of severe hypoglycemia requiring intervention from a health care professional(i.e. EMT assistance, emergency room visit, or hospital admission) within the last six (6) months (only applicable to subjects age 11 or older).

• Subject has had an episode of diabetic ketoacidosis (DKA) within the last (3) months (only applicable to subjects age 11 or older).

• Subject is currently participating in another clinical trial.

• Subject has donated blood within 112 days (3.7 months) prior to the beginning of the study activities (only applicable to subjects age 6 and older).

• Subject has both hemoglobin (Hb) and hematocrit levels that are below the normal ranges (only applicable to subjects age 6 and older). The low end of the normal range for Hb is as follows: for males and females aged 6-12 years old it is 11.5 g/dL; for males aged 12-17 it is 13.0 g/dL; for females aged 12-17 it is 12.0 g/dL. The low end of the normal hematocrit for males and females aged 6-12 is 35%; 37% for males aged 12-17 and 36% for females aged 12- 17).

• Subject has X-ray, MRI, CT or diathermy appointment scheduled during the period of study participation, and the appointment cannot be rescheduled for a time before study participation starts or after study participation ends.

• Subject is unsuitable for participation due to any other cause as determined by the Investigator.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Device:
• Freestyle LIbre Flash Glucose Monitoring System
System Performance will be characterized with respect to YSI reference venous plasma measurements

Locations

Country	Name	City	State
United States	Barbara Davis Center for Diabetes	Aurora	Colorado
United States	Rocky Mountain Diabetes and Osteoporosis Center	Idaho Falls	Idaho
United States	Diabetes and Glandular Disease Clinic	San Antonio	Texas
United States	Sansum Diabetes Research Institute	Santa Barbara	California

Sponsors (1)

Lead Sponsor	Collaborator
Abbott Diabetes Care

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	System Performance	System Performance will be characterized with respect to YSI reference venous plasma measurements	45 days